Jeffrey A Engelman Selected Research

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

1/2019	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.
10/2018	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey A Engelman Research Topics

Disease

124	Neoplasms (Cancer) 11/2021 - 05/2005
64	Lung Neoplasms (Lung Cancer) 01/2021 - 08/2005
34	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 03/2005
12	Breast Neoplasms (Breast Cancer) 01/2020 - 12/2005
7	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 11/2010
7	Adenocarcinoma of Lung 01/2017 - 10/2006
5	Melanoma (Melanoma, Malignant) 01/2019 - 03/2012
5	Carcinoma (Carcinomatosis) 01/2017 - 10/2006
4	Disease Progression 10/2016 - 10/2012
4	Carcinogenesis 04/2014 - 09/2010
3	Brain Neoplasms (Brain Tumor) 01/2017 - 11/2012
3	Oncogene Addiction 02/2015 - 09/2011
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 10/2018
2	Sarcoma (Soft Tissue Sarcoma) 01/2017 - 12/2011
2	Neoplasm Metastasis (Metastasis) 11/2016 - 02/2016
2	Adenocarcinoma 09/2015 - 05/2012
2	Hypersensitivity (Allergy) 08/2013 - 03/2005
2	Lymphoma (Lymphomas) 05/2012 - 05/2011
2	Insulin Resistance 08/2005 - 03/2005
1	Ovarian Neoplasms (Ovarian Cancer) 10/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019

Drug/Important Bio-Agent (IBA)

36	ErbB Receptors (EGF Receptor)IBA 01/2019 - 03/2005
28	Phosphotransferases (Kinase)IBA 01/2021 - 07/2005
28	Tyrosine Kinase InhibitorsIBA 01/2019 - 05/2005
27	Pharmaceutical PreparationsIBA 01/2021 - 06/2008
21	CrizotinibIBA 10/2016 - 10/2010
19	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 12/2008
16	Anaplastic Lymphoma KinaseIBA 01/2018 - 07/2008
16	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2016 - 05/2005
15	Gefitinib (Iressa)FDA Link 12/2011 - 03/2005
12	Biomarkers (Surrogate Marker)IBA 10/2020 - 07/2010
11	Phosphatidylinositols (Phosphatidylinositol)IBA 07/2014 - 03/2005
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2009
6	tyrosine receptor (receptor, tyrosine)IBA 01/2020 - 02/2011
6	ceritinibIBA 10/2016 - 01/2014
5	Mitogen-Activated Protein KinasesIBA 01/2017 - 11/2010
5	LigandsIBA 01/2017 - 08/2007
5	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2013 - 08/2005
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 03/2012
4	Mechanistic Target of Rapamycin Complex 1IBA 01/2019 - 07/2013
4	Cetuximab (Erbitux)FDA Link 07/2015 - 08/2005
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2015 - 02/2010
4	Small Interfering RNA (siRNA)IBA 01/2013 - 08/2008
4	AZD 6244IBA 03/2012 - 12/2008
4	Insulin (Novolin)FDA Link 12/2011 - 03/2005
3	nazartinibIBA 01/2021 - 03/2016
3	SHP099IBA 01/2020 - 01/2019
3	navitoclaxIBA 01/2019 - 03/2015
3	lorlatinibIBA 01/2018 - 01/2016
3	RNA (Ribonucleic Acid)IBA 12/2017 - 09/2011
3	alectinibIBA 11/2016 - 11/2014
3	Trastuzumab (Herceptin)FDA Link 02/2016 - 08/2007
3	Proto-Oncogene Proteins c-metIBA 01/2016 - 03/2010
3	AlpelisibIBA 01/2015 - 07/2013
3	TOR Serine-Threonine KinasesIBA 03/2014 - 12/2008
3	Protein Kinases (Protein Kinase)IBA 12/2013 - 11/2010
3	MitogensIBA 07/2013 - 06/2010
2	Tyrosine (L-Tyrosine)FDA Link 01/2021 - 07/2011
2	Protein Isoforms (Isoforms)IBA 01/2021 - 01/2015
2	CytokinesIBA 01/2021 - 04/2014
2	Protein Tyrosine PhosphatasesIBA 12/2019 - 02/2016
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019 - 03/2012
2	trametinibIBA 01/2019 - 01/2016
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2019 - 12/2012
2	Circulating Tumor DNAIBA 01/2018 - 03/2016
2	Immune Checkpoint InhibitorsIBA 01/2018 - 09/2016
2	DNA (Deoxyribonucleic Acid)IBA 12/2017 - 05/2008
2	Phenobarbital (Luminal)FDA Link 01/2017 - 01/2015
2	B7-H1 AntigenIBA 01/2017 - 02/2016
2	Transcription Factors (Transcription Factor)IBA 11/2016 - 06/2010
2	rociletinibIBA 04/2016 - 07/2015
2	human ERBB2 proteinIBA 02/2016 - 03/2010
2	NucleotidesIBA 07/2015 - 08/2013
2	Biological ProductsIBA 07/2015 - 06/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2015 - 12/2005
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2015 - 11/2012
2	NVP-TAE684IBA 03/2014 - 05/2011
2	Protein Kinase CIBA 12/2013 - 12/2011
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 09/2013 - 06/2010
2	5- ((2,6- dichlorobenzyl)sulfonyl)- 3- ((3,5- dimethyl- 4- ((2- (pyrrolidin- 1- ylmethyl)pyrrolidin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- 1,3- dihydro- 2H- indol- 2- oneIBA 05/2013 - 02/2011
2	Epidermal Growth Factor (EGF)IBA 11/2012 - 05/2008
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 05/2012 - 05/2011
2	Monoclonal AntibodiesIBA 12/2011 - 07/2008
2	Neuregulin-1 (Neuregulin 1)IBA 09/2011 - 03/2010
2	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 04/2011 - 06/2010
2	dactolisibIBA 11/2009 - 12/2008
1	Chemotactic FactorsIBA 01/2021
1	naporafenibIBA 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	ribociclibIBA 01/2021
1	InterferonsIBA 12/2020
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2020
1	MTOR InhibitorsIBA 01/2019
1	Surface Antigens (Surface Antigen)IBA 10/2018

Therapy/Procedure

74	Therapeutics 11/2021 - 03/2005
7	Drug Therapy (Chemotherapy) 10/2020 - 05/2008
5	Aftercare (After-Treatment) 01/2018 - 07/2013
3	Immunotherapy 01/2021 - 01/2017